Focus medicines index
Explore our range of resources, listed by the name of the medicine on which they focus.
Click the links below to view.
Amgevita (adalimumab biosimilar)
- Humira to Amgevita - Experience from over the ditch (recorded webinar)
- Bulletin #11: Adalimumab biosimilar improves access (article)
- Transition to adalimumab biosimilar (article)
- The patient voice: Moving to Amgevita (video)
- Adalimumab Q&A
Biological medicines
- Biological medicines resource hub
- Bulletin #7: Biosimilars: A promising new era (article)
- Introduction to biological medicines (article, videos, quizzes)
Cilazapril
- Heart failure therapy: From past to present (recorded webinar)
- Switching blood pressure medications - it's time to break the cilazapril habit (article)
- Bulletin #5: Cilazapril unplugged - what alternatives? (article)
- EPiC Cilazapril - view your prescribing data (dashboard)
COVID-19 oral antiviral medicines
- New antiviral targets COVID-19 (bulletin)
- Treating COVID-19 with Paxlovid in primary care (article)
- Molnupiravir for mild to moderate COVID-19 (article)
Dulaglutide and empagliflozin
- Dulaglutide and empagliflozin: Your questions answered - Part 2 (Q&A)
- Dulaglutide and empagliflozin: Your questions answered - Part 1 (Q&A)
- Dulaglutide: the long-awaited new agent to treat type 2 diabetes (recorded webinar)
- Can you say dulaglutide? (video)
- Can you say empagliflozin? (video)
- Initiating treatment with dulaglutide: Algorithms, notes and talking points (printable notes)
- Initiating treatment with empagliflozin: Algorithms, notes and talking points (printable notes)
- Bulletin #6: Considering new T2D agents (article)
- Starting injectable medicine: How to prepare your T2D patients (article)
- Targeting optimal HbA1c level in type 2 diabetes using appropriate blood glucose lowering medicine (reflection activity)
- Supporting patients to take the new diabetes meds: What you need to know (article)
- Starting empagliflozin in people on insulin and with good glycaemic control (article)
- Type 2 diabetes: Two medications offer fresh management paradigm (article)
- Bulletin #1: Inequities in type 2 diabetes (article)
- What's new with type 2 diabetes care in 2021? (recorded webinar)
- New medicines for type 2 diabetes (article)
- Special Authority Quick Guide for SGLT2 inhibitors for type 2 diabetes (article and printable guide)
- Inequities in diabetes (recorded webinar)
Rasagiline and selegiline
Rosuvastatin